R-GLP3

The Mechanism

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are gut hormones released after eating. They prompt insulin secretion, slow gastric emptying, and signal satiety to the brain. Synthetic receptor agonists engage those same pathways with a far longer duration of action than the natural hormones.

The compounds in this group differ by how many receptors they engage:

• THRA is a triple agonist, adding glucagon receptor activity to the dual incretin mechanism. The glucagon component is hypothesised to drive energy expenditure beyond appetite suppression alone.

Beyond the Incretin Class

Two other mechanisms sit in this category. MOTS-C is a peptide encoded within the mitochondrial genome, studied for AMPK activation, insulin sensitivity, and exercise-mimetic effects. The SLU-PP-332 / 5-Amino-1MQ oral blend pairs an estrogen-related receptor agonist with an NNMT inhibitor, targeting mitochondrial biogenesis and cellular energy metabolism rather than appetite.

What the Research Emphasises

Titration is the recurring theme across this class. Gastrointestinal effects are dose-dependent and titration-sensitive, and published protocols advance gradually rather than starting at target dose. Glucagon receptor activity heightens that sensitivity further, so slower advancement is standard.

All compounds referenced here are supplied for laboratory research only.